South Korean health authorities say treating COVID-19 patients is the government's duty by law and it will pay for anti-viral medication at an expected cost of around 765 U.S. dollars a dose.
The treatment is being seen as a game changer with COVID-19 now expected to be around forever.
South Korea is in talks with various manufacturers, and as of now, Merck and Co., Pfizer, and Roche are the pharmaceutical companies in phase 3 of clinical trials.
Merck and Co is leading the race and could even win emergency authorization use from the FDA for its drug as soon as this year.
Health authorities here say they've allocated more than 30 million U.S. dollars for this year and the next enough to secure almost 40-thousand doses.